Management of Arrhythmias in Cardiac Sarcoidosis

Clinical Cardiology

Volumn 38, Issue 10, 2015, Pages 635-640

  Rosenthal, David G ^a   Bravo, Paco E ^a   Patton, Kristen K ^a   Goldberger, Zachary D ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMIODARONE; ANTIARRHYTHMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GADOLINIUM; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PENTOXIFYLLINE; SOTALOL; THALIDOMIDE;

CATHETER ABLATION; DRUG HYPERSENSITIVITY; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATIENT CARE; PREVALENCE; REVIEW; SARCOIDOSIS; SUDDEN CARDIAC DEATH; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; COMPLICATION; TREATMENT OUTCOME;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; HUMANS; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 84945273062     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22430     Document Type: Review

References (42)

1. Kusano KF,. Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis. J Cardiol. 2013; 62: 326-327.
2. Iannuzzi MC, Rybicki BA, Teirstein AS,. Sarcoidosis. N Engl J Med. 2007; 357: 2153-2165.
3. Kandolin R, Lehtonen J, Airaksinen J, et al., Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015; 131: 624-632.
4. Birnie DH, Sauer WH, Bogun F, et al., HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11: 1305-1323.
5. Epstein AE, DiMarco JP, Ellenbogen KA, et al., ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 51: 2085-2105.
6. Schuller JL, Olson MD, Zipse MM, et al., Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011; 22: 1243-1248.
7. Zipse MM, Sauer WH,. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med. 2013; 19: 485-492.
8. Banba K, Kusano KF, Nakamura K, et al., Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007; 4: 1292-1299.
9. Kato Y, Morimoto S, Uemura A, et al., Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20: 133-137.
10. Yodogawa K, Seino Y, Shiomura R, et al., Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol. 2013; 62: 320-325.
11. Sekhri V, Sanal S, DeLorenzo LJ, et al., Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011; 7: 546-554.
12. Cooper LT Jr, Blauwet LA,. When should high-grade heart block trigger a search for a treatable cardiomyopathy? Circ Arrhythm Electrophysiol. 2011; 4: 260-261.
13. Takaya Y, Kusano KF, Nakamura K, et al., Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015; 115: 505-509.
14. Viles-Gonzalez JF, Pastori L, Fischer A, et al., Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest. 2013; 143: 1085-1090.
15. Lloyd-Jones DM, Wang TJ, Leip EP, et al., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110: 1042-1046.
16. Willner JM, Viles-Gonzalez JF, Coffey JO, et al., Catheter ablation of atrial arrhythmias in cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2014; 25: 958-963.
17. Betensky BP, Tschabrunn CM, Zado ES, et al., Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012; 9: 884-891.
18. Roberts WC, McAllister HA Jr, Ferrans VJ,. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977; 63: 86-108.
19. Kron J, Sauer W, Schuller J, et al., Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2013; 15: 347-354.
20. Blankstein R, Osborne M, Naya M, et al., Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014; 63: 329-336.
21. Greulich S, Deluigi CC, Gloekler S, et al., CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013; 6: 501-511.
22. Crawford T, Sarsam S, Mueller G, et al., The role of magnetic resonance imaging in identifying patients with cardiac sarcoidosis and preserved left ventricular function in predicting future ventricular arrhythmias. J Am Coll Cardiol. 2012; 59 (13 suppl 1):E575.
23. Kumar S, Barbhaiya C, Nagashima K, et al., Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015; 8: 87-93.
24. Furushima H, Chinushi M, Sugiura H, et al., Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004; 27: 217-222.
25. Mezaki T, Chinushi M, Washizuka T, et al., Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis: requirement of defibrillator implantation for the inactive stage of cardiac sarcoidosis. Intern Med. 2001; 40: 731-735.
26. Chiu CZ, Nakatani S, Zhang G, et al., Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005; 95: 143-146.
27. Mohsen A, Jimenez A, Hood RE, et al., Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014; 25: 171-176.
28. Futamatsu H, Suzuki J, Adachi S, et al., Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging. 2006; 22: 443-448.
29. Nagai S, Yokomatsu T, Tanizawa K, et al., Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014; 53: 427-433.
30. Sahoo DH, Bandyopadhyay D, Xu M, et al., Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011; 38: 1145-1150.
31. Müller-Quernheim J, Kienast K, Held M, et al., Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999; 14: 1117-1122.
32. Demeter SL,. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest. 1988; 94: 202-203.
33. Judson MA, Baughman RP, Costabel U, et al., Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008; 31: 1189-1196.
34. Erckens RJ, Mostard RL, Wijnen PA, et al., Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012; 250: 713-720.
35. Burns AM, Green PJ, Pasternak S,. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol. 2012; 39: 289-293.
36. Denys BG, Bogaerts Y, Coenegrachts KL, et al., Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond). 2007; 112: 281-289.
37. Ermakov S, Hoffmayer KS, Gerstenfeld EP, et al., Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy. Pacing Clin Electrophysiol. 2014; 37: 90-94.
38. Koplan BA, Soejima K, Baughman K, et al., Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006; 3: 924-929.
39. Jefic D, Joel B, Good E, et al., Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009; 6: 189-195.
40. Kron J, Sauer W, Mueller G, et al., Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol. 2015; 43: 55-64.
41. Schuller JL, Zipse M, Crawford T, et al., Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012; 23: 925-929.
42. Kusumoto FM, Calkins H, Boehmer J, et al., HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014; 130: 94-125.